174 related articles for article (PubMed ID: 24935174)
21. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.
Chen S; Auletta T; Dovirak O; Hutter C; Kuntz K; El-ftesi S; Kendall J; Han H; Von Hoff DD; Ashfaq R; Maitra A; Iacobuzio-Donahue CA; Hruban RH; Lucito R
Cancer Biol Ther; 2008 Nov; 7(11):1793-802. PubMed ID: 18836286
[TBL] [Abstract][Full Text] [Related]
22. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
[TBL] [Abstract][Full Text] [Related]
24. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
25. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.
Chow HY; Jubb AM; Koch JN; Jaffer ZM; Stepanova D; Campbell DA; Duron SG; O'Farrell M; Cai KQ; Klein-Szanto AJ; Gutkind JS; Hoeflich KP; Chernoff J
Cancer Res; 2012 Nov; 72(22):5966-75. PubMed ID: 22983922
[TBL] [Abstract][Full Text] [Related]
26. Gastric cancer and concomitant renal cancer: a systematic immunohistochemical and molecular analysis.
Betge J; Pollheimer MJ; Schlemmer A; Hoefler G; Langner C
Oncol Rep; 2011 Sep; 26(3):567-75. PubMed ID: 21687951
[TBL] [Abstract][Full Text] [Related]
27. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
28. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
29. KRAS and MAPK1 gene amplification in type II ovarian carcinomas.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Sato E; Iida K; Nakayama N; Ishikawa N; Miyazaki K
Int J Mol Sci; 2013 Jul; 14(7):13748-62. PubMed ID: 23820584
[TBL] [Abstract][Full Text] [Related]
30. Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer.
Hou Q; Wu YH; Grabsch H; Zhu Y; Leong SH; Ganesan K; Cross D; Tan LK; Tao J; Gopalakrishnan V; Tang BL; Kon OL; Tan P
Cancer Res; 2008 Jun; 68(12):4623-30. PubMed ID: 18559507
[TBL] [Abstract][Full Text] [Related]
31. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
[TBL] [Abstract][Full Text] [Related]
32. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
[TBL] [Abstract][Full Text] [Related]
33. Integrative approach for prioritizing cancer genes in sporadic colon cancer.
Reid JF; Gariboldi M; Sokolova V; Capobianco P; Lampis A; Perrone F; Signoroni S; Costa A; Leo E; Pilotti S; Pierotti MA
Genes Chromosomes Cancer; 2009 Nov; 48(11):953-62. PubMed ID: 19672874
[TBL] [Abstract][Full Text] [Related]
34. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
Lee J; Seo JW; Jun HJ; Ki CS; Park SH; Park YS; Lim HY; Choi MG; Bae JM; Sohn TS; Noh JH; Kim S; Jang HL; Kim JY; Kim KM; Kang WK; Park JO
Oncol Rep; 2011 Jun; 25(6):1517-24. PubMed ID: 21424128
[TBL] [Abstract][Full Text] [Related]
35. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
36. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
37. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
38. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
39. Reconstructing targetable pathways in lung cancer by integrating diverse omics data.
Balbin OA; Prensner JR; Sahu A; Yocum A; Shankar S; Malik R; Fermin D; Dhanasekaran SM; Chandler B; Thomas D; Beer DG; Cao X; Nesvizhskii AI; Chinnaiyan AM
Nat Commun; 2013; 4():2617. PubMed ID: 24135919
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
